Back to results
US 2022/0016234 A1Published application
Anti covid-19 therapies using nucleocapsid and spike proteins
AssigneeImmunityBio, Inc.
InventorsAdrian Rice, Mohit Verma
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.
Claims20
A method of inducing immunity against an antigen in a patient, the method comprising:
- administering a vaccine composition comprising a self-adjuvanted RNA-based vaccine, wherein the RNA encodes the antigen;
- and
- administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion, and wherein the hAd5 comprises a nucleotide encoding the antigen.
Dependencies are inferred from the claim text.